[Correspondence] Colistin versus colistin plus meropenem for severe infections

Mical Paul and colleagues1 should be commended for conducting the investigator-initiated randomised trial addressing combination therapy with colistin plus meropenem. The limitations of the study have been elegantly discussed by the authors and in a Comment;2 however, a few points require further comments.

Source: The Lancet Infectious Diseases - April 19, 2018 Category: Infectious Diseases Authors: Alexandre P Zavascki Tags: Correspondence Source Type: research